A5038994564- Chronic Lymphocytic Leukemia Research
- CAR-T cell therapy research
- Multiple Myeloma Research and Treatments
- Lymphoma Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Acute Myeloid Leukemia Research
- Cancer Immunotherapy and Biomarkers
- Immune cells in cancer
- Neutropenia and Cancer Infections
- Methemoglobinemia and Tumor Lysis Syndrome
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Hematopoietic Stem Cell Transplantation
- Gastrointestinal Tumor Research and Treatment
- Virus-based gene therapy research
- Cardiac tumors and thrombi
- Phagocytosis and Immune Regulation
- Galectins and Cancer Biology
- Viral Infectious Diseases and Gene Expression in Insects
- Cytokine Signaling Pathways and Interactions
- Protein Degradation and Inhibitors
- Immunotherapy and Immune Responses
- Systemic Lupus Erythematosus Research
- T-cell and B-cell Immunology
- Frailty in Older Adults
Third Affiliated Hospital of Southern Medical University
2025
Southern Medical University
2020-2024
Nanfang Hospital
2020-2024
Beijing Hospital
2023-2024
Chinese Academy of Medical Sciences & Peking Union Medical College
2023-2024
PD-L1 has two receptors: PD-1 and CD80. Previous reports assumed that CD80 interacted in trans, but recent showed only cis PD-L1/CD80 interactions existed, prevention of on antigen-presenting cells (APCs) reduced antitumor immunity via augmenting PD-L1/PD-1 CD80/CTLA4 between T APCs. Here, using tumor-bearing mice capable trans or interactions, we show do exist tumor cells, the effects require cell expression MHC-I CD28. The blockade with both augments by expanding IFN-γ–producing CD8 +...
Abstract Purpose: The purpose of this study was to investigate the remodeling multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric receptor T (CAR-T) cell therapy. Experimental Design: We performed single-cell RNA sequencing on paired bone marrow specimens (n = 14) from seven patients with before (i.e., baseline, “day −4”) and 28”) lymphodepleted BCMA CAR-T Results: Our analysis revealed heterogeneity in gene expression profiles among cells, even those...
Chemokine C-C motif ligand 7 (CCL7) is implicated in various immune and inflammatory processes; however, its role rheumatoid arthritis (RA) remains unclear. In this study, we observed that CCL7 expression was upregulated synovial M1-polarized macrophages the serum of RA mice patients. found to promote macrophage polarization toward M1 phenotype while inhibiting M2 differentiation vitro. Furthermore, intra-articular injection recombinant protein resulted enhanced polarization, increased...
Despite recent progress in multiple myeloma (MM) treatments, most patients will relapse and require additional treatment. Intravenous daratumumab, a human IgGκ monoclonal antibody targeting CD38, has shown good efficacy the treatment of MM. A subcutaneous version daratumumab was formulated to reduce burden intravenous infusions. We aimed investigate safety Chinese with relapsed/refractory MM based on demonstrated noninferiority shorter administration time reduced infusion-related reaction...
Maintenance treatment is a pivotal part in the whole process management of multiple myeloma (MM), which further deepens response and improves survival. However, evidence maintenance non-transplant MM patients inadequate real-world practice. Here, we retrospectively analyzed efficacy survival 375 from 11 centers between 2010 2021 north China. After median seven cycles front-line regimens, there were 141, 79, 155 receiving lenalidomide (L-MT), bortezomib (B-MT), or thalidomide (T-MT),...
Abstract Background We previously reported results of a pooled analysis two zanubrutinib studies in relapsed or refractory (R/R) MCL showing better survival outcomes when is used second‐line versus later‐line. Here, we present an updated with longer follow‐up 35.2 months. Methods Data were from studies—BGB‐3111‐AU‐003 (NCT02343120) and BGB‐3111‐206 (NCT03206970) R/R MCL. The patients divided into groups based on the treatment line zanubrutinib: later‐line group. inverse propensity score...
Background Chimeric antigen receptor (CAR)-T cell has revolutionary efficacy against relapsed/refractory multiple myeloma (R/R MM). However, current CAR-T therapy several limitations including long vein-to-vein time and limited viability. Methods A 4-1BB-costimulated B-cell maturation (BCMA) integrating an independently-expressed OX40 (BCMA-BBZ-OX40) was designed generated by a traditional manufacturing process (TraditionCART) or instant platform (named InstanCART). The tumor-killing...
Background: The outcome of patients with acute myeloid leukemia (AML) aged ⩾65 years is poor. Effective treatment options are limited for AML who cannot tolerate intensive chemotherapy. Objectives: We aimed to evaluate the efficacy low-dose decitabine in previously untreated were ineligible chemotherapy based on a comprehensive geriatric assessment. Design: performed prospective, multicenter, open-label, and non-randomized study. Methods: Patients enrolled at four centers Beijing between 1...
7543 Background: B-cell malignancies evade apoptosis by overexpressing BCL-2 proteins. Approved BCL-2i venetoclax requires a slow dose ramp-up to limit risk of tumor lysis syndrome (TLS) and has been associated with severe neutropenia. Investigational single-agent lisaftoclax is novel, oral active against hematologic (HMs), potentially synergistic antitumor effects when combined other agents in malignancies. Methods: The aim this multicenter open-label study was evaluate dose-limiting...
<p>Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<p>Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering Cells within MM Microenvironment.</p>
<p>Supplementary Figure S4. Quality Control of the Public scRNA-seq Dataset and Clustering Cells within MM Microenvironment.</p>
<p>Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.</p>
<p>Supplementary Figure S1. Quality Control of the scRNA-seq Data.</p>
<p>Supplementary Figure S1. Quality Control of the scRNA-seq Data.</p>
<div>AbstractPurpose:<p>The purpose of this study was to investigate the remodeling multiple myeloma microenvironment after B-cell maturation antigen (BCMA)–targeted chimeric receptor T (CAR-T) cell therapy.</p>Experimental Design:<p>We performed single-cell RNA sequencing on paired bone marrow specimens (<i>n</i> = 14) from seven patients with before (i.e., baseline, “day −4”) and 28”) lymphodepleted BCMA CAR-T therapy.</p>Results:<p>Our...
<p>Supplementary Figure S2. Clustering of the Cells within MM Microenvironment.</p>
<p>Supplementary Figure S2. Clustering of the Cells within MM Microenvironment.</p>
<p>Supplementary Figure S3. Cytogenetic Abnormality-associated Gene Expression and Clonal Evolution in MM Cells.</p>
<p>Supplementary Figure S5. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>
<p>Supplementary Figure S6. BCMA CAR-T Therapy Enhances the Proportion and Cytotoxic Activity of CD8+ Effector T Cells, Positively Correlating with Therapeutic Responsivity.</p>